Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)

Trial Profile

A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Feb 2019

At a glance

  • Drugs SHP 647 (Primary)
  • Indications Ulcerative colitis
  • Focus Registrational; Therapeutic Use
  • Acronyms FIGARO UC 303
  • Sponsors Shire; Shire Human Genetic Therapies
  • Most Recent Events

    • 14 Nov 2018 Planned End Date changed from 8 Aug 2021 to 28 Nov 2021.
    • 19 Jul 2018 Planned End Date changed from 12 Sep 2021 to 8 Aug 2021.
    • 19 Jul 2018 Planned primary completion date changed from 12 Sep 2021 to 8 Aug 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top